...Hi, everyone. Thanks so much for joining us on day 2 of Oppenheimer's 31st Annual Healthcare Conference. My name is Mark Breidenbach. I'm part of Oppenheimer's biotech equity research team. And this afternoon, I'm pleased to be hosting a fireside chat with Iovance, which is developing autologous cell therapies for cancer. And we're joined by the company's CEO, Maria Fardis. We'll be sure to try to leave a few minutes at the end for Q&A. So I would encourage anyone in the audience who has a question to make use of the question box underneath your video. So thank you for joining us, everyone, and let's go ahead and get started. Maria, for the uninitiated, maybe you can give us a very brief introduction to the company and its core technology platform and a very quick overview of its lead programs. Maria Fardis ...